Evidence map›Paper›PMID 41179733›Full record

ReviewWorld journal of hepatology2025

Clinicopathological insights and management of liver metastases: Current advances and future perspectives.

Noura A A Ebrahim, Thoraya A Farghaly, Ahmed Abdo El-Sherif, Ahmed M Fahmy, Moamen O Othman, Neveen S Tahoun, Omnia Mohamed Korany, Aya Arafat, Reham Oreaba, Soliman M A Soliman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Liver metastases beyond classical imaging findings.Abdominal radiology (New York) · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noura A A EbrahimDepartment of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qahirah, Egypt.
Thoraya A FarghalyDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Ahmed Abdo El-SherifDepartment of Chemistry, Faculty of Science, Cairo University, Cairo 12613, Al Qahirah, Egypt.
Ahmed M FahmyDepartment of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qahirah, Egypt.
Moamen O OthmanKasr Alainy Faculty of Medicine, Cairo University, Cairo 11562, Al Qahirah, Egypt.
Neveen S TahounCytopathology Unit, Department of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qahirah, Egypt.
Omnia Mohamed KoranyDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Al Qahirah, Egypt.
Aya ArafatDepartment of Chemical and Clinical Pathology, Kasr Al-Aini faculty of Medicine, Cairo University, Cairo 11562, Al Qahirah, Egypt.
Reham OreabaDepartment of Surgical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Al Qahirah, Egypt.
Soliman M A SolimanDepartment of Chemistry, Faculty of Science, Cairo University, Cairo 12613, Al Qahirah, Egypt. sabdellatif@sci.cu.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver metastases are a leading contributor to cancer-related illness and death, occurring far more frequently than primary liver tumors. Their management remains highly challenging due to the complexity of disease behavior and the need for an individualized, multidisciplinary approach. Effective care increasingly relies on integrating sophisticated diagnostic techniques, advanced systemic and locoregional therapies, and molecularly tailored treatment strategies. This review provides an in-depth analysis of the current clinicopathological perspectives on liver metastases. It explores their epidemiology, mechanisms of spread, histological growth patterns, diagnostic imaging advancements, molecular characteristics, and therapeutic interventions. Additionally, it examines the broader implications for patient quality of life (QoL), healthcare costs, and the particular difficulties associated with managing liver metastases in pediatric patients and individuals with rare malignancies. The article outlines the diverse histopathological features and tumor-liver interface growth patterns, emphasizing their prognostic and therapeutic significance. It evaluates contemporary imaging modalities-including magnetic resonance imaging and computed tomography (CT) with hepatocyte-specific agents, positron emission tomography/CT, and contrast-enhanced ultrasound-and highlights the emerging importance of liquid biopsy and molecular profiling in shaping treatment decisions. The review discusses available treatment options such as chemotherapy, targeted agents, immunotherapies, surgical resection, liver transplantation, and various locoregional therapies. Furthermore, it addresses evolving fields like prognostic scoring systems, radiomics, artificial intelligence (AI) applications, and patient-derived organoid and xenograft models. A summary of current clinical trials and translational research initiatives reflects the fast-paced evolution of this field. The management of liver metastases is rapidly advancing, driven by precision oncology principles and collaborative, multidisciplinary care. The integration of molecular diagnostics, novel therapeutic approaches, and cutting-edge technologies-including AI and organoid-based personalized drug testing-is poised to enhance treatment selection, improve clinical outcomes, and support better QoL. These innovations hold the potential to transform the outlook for patients with liver metastases, moving toward more durable disease control in appropriately selected cases.

Indexed as

Artificial intelligenceHistopathological growth patternsLiquid biopsyLiver metastasesLocoregional treatmentMolecular profilingOrganoidsPrecision oncologyRadiomicsSystemic therapy

Identifiers

PMID41179733
PMCPMC12576715

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.